Kinase Inhibitor Therapy in CML: It's What's Inside That Counts

Ítems similars

• Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia
  per: Vainstein, Vladimir, et al.
  Publicat: (2013)
• KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors
  per: Corbin, Amie S., et al.
  Publicat: (2013)
• Mechanisms of resistance to ABL kinase inhibition in CML and the development of next generation ABL kinase inhibitors
  per: Patel, Ami B., et al.
  Publicat: (2017)
• Chronic Myeloid Leukemia: Advances in Understanding Disease Biology and Mechanisms of Resistance to Tyrosine Kinase Inhibitors
  per: Eide, Christopher A., et al.
  Publicat: (2015)
• New concepts for CML clonality
  per: Khorashad, Jamshid S., et al.
  Publicat: (2013)